SCHEMBL453476

SCHEMBL453476

COC(=O)c1cc(N)c(O)c(-c2ccc(F)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.51
MAPT P10636 3/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 2/20 0.51
IKBKB O14920 1/20 0.50
PTGS1 P23219 2/20 0.49
SLC6A4 P31645 1/20 0.49
SLC6A3 Q01959 1/20 0.49
PTGS2 P35354 2/20 0.45
GAA P10253 2/20 0.45
ATM Q13315 2/20 0.45
GLA P06280 1/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45
HSD17B10 Q99714 1/20 0.45
RELA Q04206 3/20 0.45
LMNA P02545 2/20 0.44
POLB P06746 1/20 0.44
NFKB1 P19838 1/20 0.44
XDH P47989 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL452451 0.87 KDM4E (0.52) KDM4EMAPTALDH1A1HPGDIKBKB
SCHEMBL443326 0.85 EGFR (0.55) KDM4EMAPTALDH1A1HPGDPTGS2
SCHEMBL452184 0.83 PTGS1 (0.49) KDM4EMAPTALDH1A1HPGDIKBKB
SCHEMBL453504 0.79 ERN1 (0.52) KDM4EMAPTPTGS1SLC6A4SLC6A3
SCHEMBL5924237 0.78 KDM4E (0.63) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL752914 0.77 KDM4E (0.58) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL30152820 0.77 KDM4E (0.58) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL2941838 0.77 PTGS1 (0.55) KDM4EMAPTALDH1A1HPGDIKBKB
Hydrochloric Acid SCHEMBL9064595 0.76 KDM4E (0.61) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL4423037 0.76 EGFR (0.61) KDM4EMAPTALDH1A1HPGDPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238647-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2016-01-19 US disclosed
EP-2410857-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2014-01-29 EP disclosed
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain MERCK SHARP & DOHME LLC 2012-03-15 US disclosed
EP-2410857-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2012-02-01 EP disclosed
WO-2010111058-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain P2RX3, P2RX1, P2RX2 KDM4E 4010/4885MAPT 4011/4885ALDH1A1 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.